BRPI0606445A2 - inibidores de hipersecreÇço de mucina e mÉtodos de uso - Google Patents

inibidores de hipersecreÇço de mucina e mÉtodos de uso

Info

Publication number
BRPI0606445A2
BRPI0606445A2 BRPI0606445-0A BRPI0606445A BRPI0606445A2 BR PI0606445 A2 BRPI0606445 A2 BR PI0606445A2 BR PI0606445 A BRPI0606445 A BR PI0606445A BR PI0606445 A2 BRPI0606445 A2 BR PI0606445A2
Authority
BR
Brazil
Prior art keywords
methods
amino acid
acid sequence
peptides
inhibitors
Prior art date
Application number
BRPI0606445-0A
Other languages
English (en)
Inventor
Indu Parikh
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of BRPI0606445A2 publication Critical patent/BRPI0606445A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

INIBIDORES DE HIPERSECREÇçO DE MUCINA E MÉTODOS DE USO. São proporcionados peptideos que compreendem menos que 24 aminoácidos. Os peptideos têm uma seqUência de aminoácidos selecionada do grupo que consiste em: (a) uma seqüência de aminoácidos tendo de 4 a 23 aminoácidos contíguos de uma seqUência de referência, PEPTÍDEO 1; (b) uma seqUência de aminoácidos substancialmente idêntica à seqUência definida em (a); e (c) uma variante da seqUência de aminoácidos definida em (a) . É também descrito um peptídeo MANS não miristoilado. Vários métodos de uso dos peptídeos são também fornecidos.
BRPI0606445-0A 2005-01-20 2006-01-20 inibidores de hipersecreÇço de mucina e mÉtodos de uso BRPI0606445A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64529305P 2005-01-20 2005-01-20
PCT/US2006/002032 WO2006078899A2 (en) 2005-01-20 2006-01-20 Mucin hypersecretion inhibitors based on the structure of mans and methods of use

Publications (1)

Publication Number Publication Date
BRPI0606445A2 true BRPI0606445A2 (pt) 2009-03-10

Family

ID=36297369

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606445-0A BRPI0606445A2 (pt) 2005-01-20 2006-01-20 inibidores de hipersecreÇço de mucina e mÉtodos de uso

Country Status (15)

Country Link
US (5) US7524926B2 (pt)
EP (2) EP1858538B1 (pt)
JP (1) JP4926979B2 (pt)
KR (2) KR101445859B1 (pt)
CN (1) CN101146545B (pt)
AU (1) AU2006206331B2 (pt)
BR (1) BRPI0606445A2 (pt)
CA (1) CA2595406C (pt)
IL (2) IL184731A (pt)
MX (1) MX2007008744A (pt)
NZ (2) NZ560412A (pt)
RU (1) RU2423379C2 (pt)
SG (1) SG162791A1 (pt)
WO (1) WO2006078899A2 (pt)
ZA (1) ZA200706339B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
MX2007008744A (es) 2005-01-20 2008-03-10 Biomarck Pharmaceuticals Ltd Inhibidores de hipersecrecion de mucina con base en la estructura de mans ymetodos de uso.
CA2658949C (en) * 2006-07-26 2014-04-22 Biomarck Phamaceuticals, Ltd. Inhibition of marcks-mediated degranulation by marcks n-terminal pepetides in treating inflammation
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
AU2014247979B2 (en) 2013-04-05 2018-06-28 Biomarck Pharmaceuticals, Ltd. Inhibitors of metastasis
JP6965646B2 (ja) 2017-09-06 2021-11-10 株式会社ダイフク 搬送車、及び、搬送設備
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법
EP3982928A4 (en) * 2019-06-17 2023-07-19 Biomarck Pharmaceuticals, Ltd. PEPTIDES AND METHODS FOR THEIR USE IN THE TREATMENT OF UVEITIS
WO2023150791A1 (en) * 2022-02-07 2023-08-10 Biomarck Pharmaceuticals, Ltd. Peptides and methods of use thereof in treating ocular disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
CA2003316A1 (en) 1988-11-18 1990-05-18 John F. Oram Hdl-binding proteins
US5223421A (en) 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
EP0551432A1 (en) 1990-10-02 1993-07-21 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
AU2240492A (en) 1991-06-20 1993-01-25 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
JPH10502333A (ja) 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
ATE279206T1 (de) 1999-02-24 2004-10-15 Univ North Carolina State Zusammensetzungen zur modulierung der schleimsekretion
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7709300A (en) 1999-09-24 2001-04-24 Linden Technologies, Inc. Drug discovery using gene expression profiling
DK1104758T3 (da) * 1999-12-03 2003-10-20 Pfizer Prod Inc Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
JP2004049133A (ja) * 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) * 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
MX2007008744A (es) 2005-01-20 2008-03-10 Biomarck Pharmaceuticals Ltd Inhibidores de hipersecrecion de mucina con base en la estructura de mans ymetodos de uso.
CA2658949C (en) 2006-07-26 2014-04-22 Biomarck Phamaceuticals, Ltd. Inhibition of marcks-mediated degranulation by marcks n-terminal pepetides in treating inflammation

Also Published As

Publication number Publication date
NZ560412A (en) 2009-06-26
CN101146545B (zh) 2012-12-26
CN101146545A (zh) 2008-03-19
US20150274778A1 (en) 2015-10-01
AU2006206331A2 (en) 2006-07-27
KR20140093737A (ko) 2014-07-28
US20060205664A1 (en) 2006-09-14
KR101445859B1 (ko) 2014-11-04
IL228531A0 (en) 2013-12-31
EP2399599A3 (en) 2012-04-18
AU2006206331A1 (en) 2006-07-27
AU2006206331B2 (en) 2012-08-30
US8907056B2 (en) 2014-12-09
US8293870B2 (en) 2012-10-23
IL184731A (en) 2013-10-31
MX2007008744A (es) 2008-03-10
CA2595406A1 (en) 2006-07-27
EP1858538B1 (en) 2019-03-27
CA2595406C (en) 2017-07-11
KR20070107052A (ko) 2007-11-06
KR101554653B1 (ko) 2015-10-06
RU2423379C2 (ru) 2011-07-10
US20130338085A1 (en) 2013-12-19
US7524926B2 (en) 2009-04-28
EP1858538A2 (en) 2007-11-28
US9598463B2 (en) 2017-03-21
IL184731A0 (en) 2007-12-03
JP2008528500A (ja) 2008-07-31
ZA200706339B (en) 2008-09-25
EP2399599A2 (en) 2011-12-28
RU2007131424A (ru) 2009-02-27
SG162791A1 (en) 2010-07-29
US8492518B2 (en) 2013-07-23
US20100197607A1 (en) 2010-08-05
NZ577196A (en) 2011-06-30
JP4926979B2 (ja) 2012-05-09
US20090275520A1 (en) 2009-11-05
WO2006078899A3 (en) 2006-12-21
WO2006078899A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
BRPI0606445A2 (pt) inibidores de hipersecreÇço de mucina e mÉtodos de uso
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
AR051512A1 (es) Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"
UY27643A1 (es) Formas de dosificación farmacéutica de liberación controlada de un inhibidor de la proteína de transferencia del éster de colesterilo
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
WO2003096984A3 (en) Drug therapy for celiac sprue
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
BR0112666A (pt) Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
BR9910639A (pt) Drogas anti-angiogênicas compreendendo peptìdeo
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
ES2513392T3 (es) Materiales biológicos y usos de los mismos
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
ES2531480T3 (es) Péptidos derivados de la proteína bplp humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
BR0116698A (pt) Composto de modafinila e misturas de ciclodextrina, uso e método de obtenção dos mesmos
BR0314450A (pt) Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
BRPI0508951A (pt) composição apropriada para fazer pelìculas, pelìcula produzida a partir da composição, artigo moldado, método de cultivo de safras, e, pelìcula à base de proteìna
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements